跳至主要内容
临床试验/JPRN-UMIN000002022
JPRN-UMIN000002022已完成1 期

Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent pancreatic cancer to be refractory to chemotherapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularization - Phase I / II clinical trial of peptide vaccination therapy for pancreatic cancer

Department of Gastroenterology, Juntendo University School of Medicine0 个研究点目标入组 36 人开始时间: 2009年5月31日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 85years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients have uncontrollable associated cancer. 2. Patients have uncontrollable severe infectional diseases. 3. Patients have severe trauma. 4. Patients who are treated with steroid or immunotherapy during clinical trial. 5. Pregnancy or lactation. 6. Patients who have non-recovered injury. 7. Patients judged inappropriated by doctors.

研究者

发起方
Department of Gastroenterology, Juntendo University School of Medicine

相似试验